TIL Therapy Pipeline Summary

• The TIL Therapy Pipeline is advancing rapidly, with several biopharmaceutical companies developing innovative therapies aimed at improving disease control, reducing symptom burden, and addressing unmet patient needs.
• The leading TIL Therapy Companies include TILT Therapeutics, Grit Biotechnology, Instil Bio, Iovance Biotherapeutics, Lyell Immunopharma, Phio Pharmaceuticals, Turnstone Biologics, Shanghai Gencells Therapeutics, Shanghai OriginCell Therapeutics, AgonOx, Obsidian Therapeutics, Nurix Therapeutics, KSQ Therapeutics, Turnstone Biologics, Genocea, Achilles Therapeutics, and others.

Request for unlocking the Sample Page of “TIL Therapy Pipeline”

Key Factors Driving the Growth of the TIL Therapy Pipeline

• Growing Need for Effective Solid Tumor Therapies

Solid tumors remain challenging to treat with existing cellular immunotherapies, creating significant demand for new approaches. TIL therapy offers a way to harness naturally occurring anti-tumor T cells already present within tumors.

• Clinical Validation of TIL Therapy

The FDA approval of lifileucel (Amtagvi) for advanced melanoma established an important clinical and regulatory precedent for TIL-based therapies and has encouraged further development across solid tumor indications.

• Durable Responses in Treatment-Resistant Cancer

Clinical evidence showing meaningful and durable responses in patients who have progressed after checkpoint inhibitor therapy is increasing interest in TIL therapy, particularly for difficult-to-treat cancers with limited treatment alternatives.

• Expansion into Multiple Solid Tumor Indications

Developers are investigating TIL therapies beyond melanoma, including lung, gastrointestinal, sarcoma, and other solid tumors. This expansion is broadening the potential patient population and creating new opportunities for pipeline growth.

• Advancements in TIL Engineering

Next-generation programs are incorporating gene editing and other engineering approaches to enhance T-cell persistence, tumor recognition, potency, and resistance to the immunosuppressive tumor microenvironment.

• Improvements in Manufacturing and Scalability

Advances in centralized manufacturing, standardized production processes, quality control, and potency testing are helping address the historical complexity of personalized TIL production and supporting broader clinical development.

• Combination with Immunotherapies

TIL therapy is increasingly being explored alongside immune checkpoint inhibitors and other immunomodulatory approaches. Such combinations may enhance T-cell activity and persistence while addressing mechanisms of tumor immune evasion.

• Advances in Tumor Microenvironment Research

Improved understanding of the immunosuppressive tumor microenvironment is helping researchers develop strategies to improve TIL infiltration, recognition, persistence, and anti-tumor activity. These advances are supporting the development of more effective next-generation therapies.

DelveInsight’s “TIL Therapy Pipeline Insight, 2026,” report provides comprehensive insights about 15+ companies and 20+ pipeline drugs in the TIL Therapy pipeline landscape. It covers the TIL Therapy Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the TIL Therapy Therapeutics Assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive TIL Therapy Pipeline products in this space. 

Geography Covered

• Global coverage

TIL Therapy Pipeline Understanding

TIL Therapy Overview

TIL (tumor-infiltrating lymphocyte) therapy is a type of cellular immunotherapy that may be used to treat head and neck squamous cell carcinoma, melanoma, lung cancer, genitourinary cancers, and a growing list of other malignancies. Cellular immunotherapy leverages components of the patient’s own immune system to seek out and attack specific cancer cells.

Because TILs come directly from the tumor, they already recognize many targets on the cancer cells. This makes them a very attractive therapy. Engineering TILs enhances their ability to fight the cancer cells. Currently, TIL therapies are only available through clinical trials. Currently, TIL Therapy can be used to treat melanoma, variations of carcinoma, lung cancer, breast cancer, and genitourinary cancer.

"TIL Therapy - Pipeline Insight, 2026" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the TIL Therapy Pipeline landscape is provided which includes the disease overview and TIL Therapy treatment guidelines. The assessment part of the report embraces, in depth TIL Therapy commercial assessment and clinical assessment of the pipeline products under development. In the TIL Therapy Pipeline Report, detailed description of the drug is given which includes TIL Therapy Mechanism of Action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, TIL Therapy collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

TIL Therapy Pipeline Report Highlights

The TIL Therapy Companies and academics are working to assess challenges and seek opportunities that could influence TIL Therapy R&D. The TIL Therapy Therapies under development are focused on novel approaches to treat/improve TIL Therapy.

TIL Therapy Emerging Drugs Chapters

This segment of the TIL Therapy Pipeline Report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand TIL Therapy Clinical Trials details, expressive pharmacological action, agreements and collaborations, and the latest TIL Therapy news and press releases.

TIL Therapy Emerging Drugs

• LN-145: Iovance Therapeutics

Autologous tumour infiltrating lymphocytes is derived through isolation of a patient’s own naturally occurring TIL from a sample of cancerous tumor removed from the patient. The expanded and engineered TIL are then administered via intravenous infusion back to the patient as LN-145 (TIL Therapy), with the intention that the TIL will target and infiltrate cancer in the patient and attack the cancer in greater number. It is currently being evaluated in Phase II clinical trial for the treatment of cervical cancer; colorectal cancer; Head and neck cancer; malignant melanoma; and non-small cell lung cancer.

• ITIL-168: Instil Bio

ITIL-168 is an investigational, autologous cell therapy made from tumor infiltrating lymphocytes, or TILs. ITIL-168 is manufactured with Instil’s proprietary, optimized, and scalable manufacturing process, which has been designed to capture and preserve the maximum diversity of each patient’s TILs; the manufacturing process also offers significant scheduling flexibility for patients and physicians at the time of both tumor resection and TIL treatment. The therapy is being investigated in Phase II stage of development for the treatment of malignant melanoma.

Further product details are provided in the report……..

TIL Therapy Pipeline Therapeutic Assessment

This segment of the TIL Therapy Pipeline Report provides insights about the different TIL Therapy Drugs segregated based on the following parameters that define the scope of the report, such as:

• Major TIL Therapy Companies

There are approx. 15+ key companies that are developing therapies for TIL Therapy. The TIL Therapy Companies which have their TIL Therapy drug candidates in the most advanced stage, i.e. Phase II include, Iovance Therapeutics.

TIL Therapy Phases

DelveInsight’s TIL Therapy Pipeline Report covers around 15+ products under different phases of clinical development like

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage products (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

TIL Therapy Pipeline Report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical.
• Molecule Type

TIL Therapy Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type

TIL Therapy Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

TIL Therapy Clinical Trials Activities

The TIL Therapy Pipeline Report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses TIL Therapy therapeutic drugs and key players involved in developing key drugs.

TIL Therapy Pipeline Development Activities

The TIL Therapy Pipeline Report covers detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging TIL Therapy drugs.

TIL Therapy Pipeline Report Insights

• TIL Therapy Pipeline Analysis
• Therapeutic Assessment
• TIL Therapy Unmet Needs
• Impact of TIL Therapy Drugs

TIL Therapy Pipeline Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions Answered in the TIL Therapy Pipeline Report

Current TIL Therapy Treatment Scenario and Emerging Therapies:

• How many companies are developing TIL Therapy Drugs?
• How many TIL Therapy Drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of TIL Therapy?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the TIL Therapy therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for TIL Therapy and their status?
• What are the key designations that have been granted to the emerging drugs?

Stay updated with us for Recent Articles @ New DelveInsight Blogs